Latest News

  • 04/09/2015
    Associate Professor Peter Dearden has been granted $1,000,000 for phase two of his Selective insecticides project. He was funded just under $1m in 2013 for phase one, and progress has been such that MBIE has continued the funding for another two years.
    Read more »
  • 21/08/2015
    Scientist of Year
    Dr Colin Jackson, who did his undergraduate degree in the Department of Biochemistry here at Otago, has been named the ACT's first Scientist of the Year.
    Read more »
  • 20/08/2015
    Tanya Flynn2
    Merriman Lab PhD student Tanya Flynn was interviewed by Jim Mora yesterday afternoon about her work on tomatoes as a trigger of gout attacks. This work has also been highlighted on the University of Otago website.
    Read more »
  • Event Calendar

    S M T W T F S  
    30 31 01 02 03 04 05 «
    06 07 08 09 10 11 12 «
    13 14 15 16 17 18 19 «
    20 21 22 23 24 25 26 «
    27 28 29 30 01 02 03 «
    Show events for month  

    This calendar shows scheduled speaking events such as seminars and journal clubs. Dates with events scheduled are highlighted in blue, click on one of these to go to a page of event details.

    The small arrows pointing at each week are links to that week's events.

  • Featured publication

    Michael B Mann, Michael A Black, Devin J Jones, Jerrold M Ward, Christopher Chin Kuan Yew, Justin Y Newberg, Adam J Dupuy, Alistair G Rust, Marcus W Bosenberg, Martin McMahon, Cristin G. Print, Neal G Copeland, and Nancy A Jenkins., Nat Genet, 2015.

    A specific base mutation of the BRAF gene, called BRAF-V600E, is found in 70 percent or more of benign birthmarks and moles in humans, and has long been believed to precede the development of melanomas, even though the BRAF mutation alone does not seem to be enough to cause cancer. Using a "Sleeping Beauty” (SB) mouse model of melanoma (in which transposon insertions mimic gene mutations), this paper aimed to identify the genes and pathways that cooperate with the BRAF mutation to cause skin cancer.  Of the 1,232 candidate cancer genes found to interact with BRAF in tumour development, more than 500 of these had human equivalents that either showed increased mutation rates in melanoma, or were associated with patient prognosis.  In addition, the gene CEP350 was identified and validated as a new tumor-suppressor gene in human melanoma.

    More publications »

  • Related sites